
AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens
The company noted that no new safety concerns were identified with the combination of Imfinzi and BCG induction and maintenance therapy in the trial. Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported …